Stifel Starts Cue Biopharma (CUE) at Buy

April 8, 2020 4:22 PM EDT
Get Alerts CUE Hot Sheet
Price: $13.19 -3.01%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 8 | New: 61
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Stephan Willey initiates coverage on Cue Biopharma (NASDAQ: CUE) with a Buy rating and a price target of $21.00.

The analyst comments "We believe the Immuno-STAT platform from which the company’ wholly-owned and partnered pipeline of clinical/preclinical candidates is derived represents a highly-novel/versatile approach to selectively and safely harnessing the intrinsic immune response required for the treatment of cancer and autoimmune disease. We believe CUE-101 – the centerpiece of our investment thesis and valuation – has the potential to transform the treatment of HPV-driven malignancies (via a combination of TCR specificity and IL-2-mediated activation) across a spectrum of major HLA allele subtypes. We expect multiple FY20 data disclosures from the ongoing P1 development program in SCCHN patients to yield potentially significant near-term value creation opportunities and improve visibility into the company’s ability to successfully leverage the modularity of the technology to fuel additional pipeline expansion. We view existing strategic partnerships with LG Chem (oncology) and Merck (autoimmune disease) as opportunities to both expand development/ commercial breadth and provide longer-term access to non-dilutive capital."

For an analyst ratings summary and ratings history on Cue Biopharma click here. For more ratings news on Cue Biopharma click here.

Shares of Cue Biopharma closed at $15.07 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities